Colorectal cancer is one of the most frequent causes of cancer-associated mortality worldwide. Despite the introduction of new drugs and the continuous improvement in survival over the last two decades in patients with metastatic colorectal cancer, more than half of these patients succumb to their disease within less than 3 years.
The Berger’s Lab is focused to identify prognostic and predictive biomarkers on the DNA, mRNA and protein levels in colorectal cancer to better predict outcome and to select those patients who may benefit most from a specific treatment.
